Survey of Ophthalmology
Volume 55, Issue 2 , Pages 108-133 , March 2010

Nonsteroidal Anti-inflammatory Drugs in Ophthalmology

  • Stephen J. Kim, MD

      Affiliations

    • Department of Ophthalmology, Vanderbilt University, Nashville, Tennessee, USA
    • Corresponding Author InformationReprint address: Steven J Kim, MD, Vanderbilt University, Ophthalmology, 2311 Pierce Avenue, Nashville, TN 37232, United States.
    • ,
  • Allan J. Flach, MD

      Affiliations

    • Department of Ophthalmology, University of California and Veterans Administration, San Francisco, California, USA
    • ,
  • Lee M. Jampol, MD

      Affiliations

    • Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

References 

  1. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2. Ophthalmology. 1998;105(9):1780–1786
  2. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115(9):1447–9, 1449. e1-10
  3. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. Diabetes. 1989;38(4):491–498
  4. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98(5 Suppl):757–765
  5. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long-term cystoid macular edema. Italian Diclofenac Study Group. J Cataract Refract Surg. 1997;23(8):1183–1189
  6. The First International Cystoid Macular Edema Symposium. Sarasota, Florida, April 1983. Surv Ophthalmol. 1984;28(Suppl):131–619
  7. Age-related Eye Disease Study Research Group. Risk factors associated with age-related nuclear and cortical cataract:a case-control study in the Age-Related Eye Disease Study, AREDS Report No. 5. Ophthalmology. 2001;108(8):1400–8
  8. Abelson MB, Butrus SI, Weston JH. Aspirin therapy in vernal conjunctivitis. Am J Ophthalmol. 1983;95(4):502–505
  9. Abelson MB, Schaefer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol. 1993;38(Suppl):115–132
  10. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008;30(2):65–68
  11. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118(4):445–450
  12. Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS J. 2008;10(2):229–241
  13. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92(23):10457–10461
  14. Akpek EK, Uy HS, Christen W, et al. Severity of episcleritis and systemic disease association. Ophthalmology. 1999;106(4):729–731
  15. Allansmith MR, Ross RN. Ocular allergy and mast cell stabilizers. Surv Ophthalmol. 1986;30(4):229–244
  16. Almeida DR, Johnson D, Hollands H, et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. J Cataract Refract Surg. 2008;34(1):64–69
  17. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib–PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 2006;47(3):1149–1160
  18. Amrite AC, Kompella UB. Celecoxib inhibits proliferation of retinal pigment epithelial and choroid–retinal endothelial cells by a cyclooxygenase-2-independent mechanism. J Pharmacol Exp Ther. 2008;324(2):749–758
  19. Apt L, Voo I, Isenberg SJ. A randomized clinical trial of the nonsteroidal eyedrop diclofenac after strabismus surgery. Ophthalmology. 1998;105(8):1448–1452discussion 1453–4
  20. Ares JJ, Outt PE. Gastroprotective agents for the prevention of NSAID-induced gastropathy. Curr Pharm Des. 1998;4(1):17–36
  21. Armaly MF, Becker B. Intraocular pressure response to topical corticosteroids. Fed Proc. 1965;24(6):1274–1278
  22. Armaly MF. Dexamethasone ocular hypertension in the clinically normal eye. II. The untreated eye, outflow facility, and concentration. Arch Ophthalmol. 1966;75(6):776–782
  23. Asai T, Nakagami T, Mochizuki M, et al. Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. Cornea. 2006;25(2):224–227
  24. Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol. 2003;136(4):593–602
  25. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol. 2003;458(3):283–289
  26. Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res. 2004;21(10):1797–1804
  27. Baklayan GA, Patterson HM, Song CK, et al. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther. 2008;24(4):392–398
  28. Ballas Z, Blumenthal M, Tinkelman DG, et al. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol. 1993;38(Suppl):141–148
  29. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372(9651):1756–1764
  30. Bauer AM, Fiehn C, Becker MD. Celecoxib, a selective inhibitor of cyclooxygenase 2 for therapy of diffuse anterior scleritis. Am J Ophthalmol. 2005;139(6):1086–1089
  31. Bekendam PD, Narvaez J, Agarwal M. Case of corneal melting associated with the use of topical nepafenac. Cornea. 2007;26(8):1002–1003
  32. Benson SE, Ratcliffe S, VAN Raders P, et al. A randomised comparison of parecoxib/valdecoxib and placebo for the prevention of cystoid macular edema after scleral buckling surgery. Retina. 2009;29(3):387–394
  33. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1–32
  34. Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunol Allergy Clin North Am. 2008;28(1):43–58vi
  35. Birt CM. The use of topical ketorolac 0.5% for pain relief following cyclophotocoagulation. Ophthalmic Surg Lasers Imaging. 2003;34(5):381–385
  36. Biswas J, Ganeshbabu TM, Raghavendran SR, et al. Efficacy and safety of 1% rimexolone versus 1% prednisolone acetate in the treatment of anterior uveitis––a randomized triple masked study. Int Ophthalmol. 2004;25(3):147–153
  37. Blaydes JEJ, Kelley EP, Walt JG, et al. Flurbiprofen 0.03% for the control of inflammation following cataract extraction by phacoemulsification. J Cataract Refract Surg. 1993;19(4):481–487
  38. Blumenthal M, Robin A, Ritch R, et al. Flurbiprofenadministered topically to secondary glaucoma patients undergoing argon laser trabeculoplasty. Ophthalmic Laser Therapy. 1987;2:249–258
  39. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520–1528
  40. Bora PS, Sohn JH, Cruz JM, et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol. 2005;174(1):491–497
  41. Brint SF, Cheetham JK, DeGryse R, et al. Efficacy and safety of nonpreserved ketorolac ophthalmic solution in postoperative ocular pain following radial keratotomy. J Cataract Refract Surg. 1999;25(1):41–9
  42. Brooks CD, Karl KJ. Hay fever treatment with combined antihistamine and cyclooxygenase-inhibiting drugs. J Allergy Clin Immunol. 1988;81(6):1110–1117
  43. Brooks CD, Nelson AL, Metzler C. Effect of flurbiprofen, a cyclooxygenase inhibiting drug, on induced allergic rhinitis. J Allergy Clin Immunol. 1984;73(5 Pt 1):584–589
  44. Brooks CD, Nelson AL, Metzler C. Treatment of ragweed hay fever with flurbiprofen, a cyclooxygenase-inhibiting drug. Ann Allergy. 1985;55(4):557–562
  45. Brooks PM. Side-effects of non-steroidal anti-inflammatory drugs. Med J Aust. 1988;148(5):248–251
  46. Brown SI, Weller CA, Vidrich AM. Effect of corticosteroids on corneal collagenase of rabbits. Am J Ophthalmol. 1970;70(5):744–747
  47. Bucci FA, Waterbury LD, Amico LM. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification. Am J Ophthalmol. 2007;144(1):146–147
  48. Burnett J, Tessler H, Isenberg S, Tso MO. Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surg. 1983;14(2):150–152
  49. Caldwell M, Reilly C. Effects of topical nepafenac on corneal epithelial healing time and postoperative pain after PRK: a bilateral, prospective, randomized, masked trial. J Refract Surg. 2008;24(4):377–382
  50. Carmo A, Cunha-Vaz JG, Carvalho AP, Lopes MC. Effect of cyclosporin-A on the blood–retinal barrier permeability in streptozotocin-induced diabetes. Mediators Inflamm. 2000;9(5):243–248
  51. Chan CK, Lam DS. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol. 2004;137(6):1157–1158author reply 1158
  52. Chang DF, Garcia IH, Hunkeler JD, Minas T. Phase II results of an intraocular steroid delivery system for cataract surgery. Ophthalmology. 1999;106(6):1172–1177
  53. Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des. 2005;11(14):1795–1804
  54. Cheng T, Cao W, Wen R, et al. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells. Invest Ophthalmol Vis Sci. 1998;39(3):581–591
  55. Chin MS, Nagineni CN, Hooper LC, et al. Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42(10):2338–2346
  56. Chiolero A, Maillard MP, Burnier M. Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?. Expert Opin Drug Saf. 2002;1(1):45–52
  57. Congdon NG, Schein OD, von Kulajta P, et al. Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs. J Cataract Refract Surg. 2001;27(4):622–631
  58. Costagliola C, Campa C, Perri P, et al. Topical and oral ketorolac administration increases the intraocular pressure–lowering effect of latanoprost. Curr Eye Res. 2008;33(5):477–482
  59. Costagliola C, Parmeggiani F, Antinozzi PP, et al. The influence of diclofenac ophthalmic solution on the intraocular pressure–lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. Exp Eye Res. 2005;81(5):610–615
  60. Crofford LJ. Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?. Curr Opin Rheumatol. 2002;14(3):225–230
  61. Cryan LM, Paraoan L, Hiscott P, et al. Expression of COX-2 and prognostic outcome in uveal melanoma. Curr Eye Res. 2008;33(2):177–184
  62. Dadeya S, Kamlesh . Comparative evaluation of diclofenac and dexamethasone following strabismus surgery. J Pediatr Ophthalmol Strabismus. 2002;39(3):166–168
  63. Dai W, Kloner RA. Relationship between cyclooxygenase-2 inhibition and thrombogenesis. J Cardiovasc Pharmacol Ther. 2004;9(1):51–59
  64. D'Angelo G, Lambiase A, Cortes M, et al. Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2003;241(3):192–195
  65. Davies NM, Good RL, Roupe KA, Yanez JA. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error? Not as easy as 1, 2, 3. J Pharm Pharm Sci. 2004;7(2):217–226
  66. Davies T, Lederer DA, Spencer AA, McNicol GP. The effect of flurbiprofen (2-(2-fluoro-4-biphenylyl) propionic acid) on platelet function and blood coagulation. Thromb Res. 1974;5(5):667–683
  67. de Souza Filho JP, Correa ZM, Marshall JC, et al. The effect of a selective cyclooxygenase-2 (COX-2) inhibitor on the proliferation rate of retinoblastoma cell lines. Eye. 2006;20(5):598–601
  68. Deutsch TA, Hughes WF. Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas. Am J Ophthalmol. 1979;87(4):536–540
  69. Dhir SP, Garg SK, Sharma YR, Lath NK. Prostaglandins in human tears. Am J Ophthalmol. 1979;87(3):403–404
  70. Diestelhorst M, Schmidl B, Konen W, et al. Efficacy and tolerance of diclofenac sodium 0.1%, flurbiprofen 0.03%, and indomethacin 1.0% in controlling postoperative inflammation. J Cataract Refract Surg. 1996;22(Suppl 1):788–793
  71. Donnenfeld ED, Holland EJ, Durrie DS, Raizman MB. Double-masked study of the effects of nepafenac 0.1% and ketorolac 0.4% on corneal epithelial wound healing and pain after photorefractive keratectomy. Adv Ther. 2007;24(4):852–862
  72. Donnenfeld ED, Holland EJ, Stewart RH, et al. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology. 2007;114(9):1653–1662
  73. Donnenfeld ED, Perry HD, Wittpenn JR, et al. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve. J Cataract Refract Surg. 2006;32(9):1474–1482
  74. Du Y, Sarthy VP, Kern TS. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am J Physiol Regul Integr Comp Physiol. 2004;287(4):R735–R741
  75. Dunne JA, Jacobs N, Morrison A, Gilbert DJ. Efficacy in anterior uveitis of two known steroids and topical tolmetin. Br J Ophthalmol. 1985;69(2):120–125
  76. Duong HV, Westfield KC, Chalkley TH. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. J Cataract Refract Surg. 2007;33(11):1925–1929
  77. Durrie DS, Kennard MG, Boghossian AJ. Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK). Adv Ther. 2007;24(6):1278–1285
  78. Edwards AO, Ritter R, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308(5720):421–424
  79. Eiferman RA, Hoffman RS, Sher NA. Topical diclofenac reduces pain following photorefractive keratectomy. Arch Ophthalmol. 1993;111(8):1022
  80. el-Harazi SM, Ruiz RS, Feldman RM, et al. A randomized double-masked trial comparing ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing post-phacoemulsification flare and cells. Ophthalmic Surg Lasers. 1998;29(7):539–544
  81. Ellis PP, Pfoff DS, Bloedow DC, Riegel M. Intraocular diclofenac and flurbiprofen concentrations in human aqueous humor following topical application. J Ocul Pharmacol. 1994;10(4):677–682
  82. Esgin H, Samut HS. Topical ketorolac 0.5% for ocular pain relief during scatter laser photocoagulation with 532 nm green laser. J Ocul Pharmacol Ther. 2006;22(6):460–464
  83. Fan DS, Ng JS, Lam DS. A prospective study on ocular hypertensive and anti-inflammatory response to different dosages of fluorometholone in children. Ophthalmology. 2001;108(11):1973–1977
  84. Fan DS, Yu CB, Chiu TY, et al. Ocular-hypertensive and anti-inflammatory response to rimexolone therapy in children. Arch Ophthalmol. 2003;121(12):1716–1721
  85. Fekrat S, Marsh MJ, Elsing SH, et al. Intraoperative ketorolac and eye pain after viteoretinal surgery: a prospective, randomized, placebo-controlled study. Retina. 2003;23(1):8–13
  86. Fernandes BF, Marshall JC, Di Cesare S, et al. Amfenac increases the radiosensitivity of uveal melanoma cell lines. Eye. 2008;22(5):701–706
  87. Figueiredo A, Caissie AL, Callejo SA, et al. Cyclooxygenase-2 expression in uveal melanoma: novel classification of mixed-cell-type tumours. Can J Ophthalmol. 2003;38(5):352–356
  88. Flach A. Topically applied nonsteroidal anti-inflammatory drugs and corneal problems: an interim review and comment. Ophthalmology. 2000;107(7):1224–1226
  89. Flach AJ. The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies. Trans Am Ophthalmol Soc. 2008;106:138–145discussion 145–8
  90. Flach AJ. Treatment of postoperative inflammation in ophthalmology. J Toxicol Cut and Ocular Toxicol. 1991;10:253–277
  91. Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002;42(1):1–11
  92. Flach AJ. Nonsteroidal anti-inflammatory drugs. In:  Tasman W editors. Duanes Foundations of Clinical Ophthalmology, vol. 2. Philadelphia, PA: Lippincott; 1994;p. 1–32
  93. Flach AJ. Discussion: Ketorolac vs. prednisolone vs. combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology. 2000;107(11):2039
  94. Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol. 1992;36(4):259–284
  95. Flach AJ. Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs. Trans Am Ophthalmol Soc. 2001;99:205–210discussion 210–2
  96. Flach AJ. Misuse and abuse of topically applied nonsteroidal anti-inflammatory drugs. Cornea. 2006;25(10):1265–1266
  97. Flach AJ, Dolan BJ, Donahue ME, et al. Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery. Ophthalmology. 1998;105(9):1775–1779
  98. Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol. 1987;103(4):479–486
  99. Flach AJ, Dolan BJ. Incidence of postoperative posterior capsular opacification following treatment with diclofenac 0.1% and ketorolac 0.5% ophthalmic solutions: 3-year randomized, double-masked, prospective clinical investigation. Trans Am Ophthalmol Soc. 2000;98:101–105discussion 105–7
  100. Flach AJ, Graham J, Kruger LP, et al. Quantitative assessment of postsurgical breakdown of the blood–aqueous barrier following administration of 0.5% ketorolac tromethamine solution. A double-masked, paired comparison with vehicle–placebo solution study. Arch Ophthalmol. 1988;106(3):344–347
  101. Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol. 1991;112(5):514–519
  102. Flach AJ, Kraff MC, Sanders DR, Tanenbaum L. The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood–aqueous barrier. Arch Ophthalmol. 1988;106(4):480–483
  103. Flach AJ, Lavelle CJ, Olander KW, et al. The effect of ketorolac tromethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation. Ophthalmology. 1988;95(9):1279–1284
  104. Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96:557–634
  105. Flach AJ, Stegman RC, Graham J, Kruger LP. Prophylaxis of aphakic cystoid macular edema without corticosteroids. A paired-comparison, placebo-controlled double-masked study. Ophthalmology. 1990;97(10):1253–1258
  106. Fraser-Smith EB, Matthews TR. Effect of ketorolac on Candida albicans ocular infection in rabbits. Arch Ophthalmol. 1987;105(2):264–267
  107. Fraser-Smith EB, Matthews TR. Effect of ketorolac on herpes simplex virus type one ocular infection in rabbits. J Ocul Pharmacol. 1988;4(4):321–326
  108. Fraunfelder FT. Extraocular fluid dynamics: how best to apply topical ocular medication. Trans Am Ophthalmol Soc. 1976;74:457–487
  109. Friedlaender MH. Conjunctivitis of allergic origin: clinical presentation and differential diagnosis. Surv Ophthalmol. 1993;38(Suppl):105–114
  110. Frota AC, Odashiro AN, Pereira PR, et al. Immunohistochemical expression of COX-2 and c-kit in metastatic uveal melanoma. Can J Ophthalmol. 2007;42(1):145–146
  111. Frucht-Pery J, Siganos CS, Solomon A, et al. Topical indomethacin solution versus dexamethasone solution for treatment of inflamed pterygium and pinguecula: a prospective randomized clinical study. Am J Ophthalmol. 1999;127(2):148–152
  112. Frucht-Pery J, Solomon A, Siganos CS, et al. Treatment of inflamed pterygium and pinguecula with topical indomethacin 0.1% solution. Cornea. 1997;16(1):42–47
  113. Fry LL. Efficacy of diclofenac sodium solution in reducing discomfort after cataract surgery. J Cataract Refract Surg. 1995;21(2):187–190
  114. Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116(1):73–79
  115. Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000;24(4):357–370
  116. Gass JD, Norton EW. Cystoid macular edema and papilledema following cataract extraction. A fluorescein fundoscopic and angiographic study. Arch Ophthalmol. 1966;76(5):646–661
  117. Gieser DK, Hodapp E, Goldberg I, et al. Flurbiprofen and intraocular pressure. Ann Ophthalmol. 1981;13(7):831–833
  118. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113(9):1533–1538
  119. Gills JP. Voltaren associated with medication keratitis. J Cataract Refract Surg. 1994;20(1):110
  120. Goethals M, Missotten L. Efficacy and safety of indomethacin 0.1% versus flurbiprofen 0.03% eyedrops in inflammation after argon laser trabeculoplasty. The Belgian Study Group on Glaucoma. Doc Ophthalmol. 1994;85(3):287–293
  121. Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf. 2006;15(4):213–220
  122. Gordon YJ, Araullo-Cruz T, Romanowski EG. The effects of topical nonsteroidal anti-inflammatory drugs on adenoviral replication. Arch Ophthalmol. 1998;116(7):900–905
  123. Greaves MW, McDonald-Gibson W. Itch: role of prostaglandins. Br Med J. 1973;3(5881):608–609
  124. Green K, Bowman K, Luxenberg MN, Friberg TR. Penetration of topical indomethacin into phakic and aphakic rabbit eyes. Arch Ophthalmol. 1983;101(2):284–288
  125. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006;98(11):736–747
  126. Guadagni F, Ferroni P, Palmirotta R, et al. Non-steroidal anti-inflammatory drugs in cancer prevention and therapy. Anticancer Res. 2007;27(5A):3147–3162
  127. Gupta S, Khurana AK, Ahluwalia BK, Gupta NC. Topical indomethacin for vernal keratoconjunctivitis. Acta Ophthalmol (Copenh). 1991;69(1):95–98
  128. Gwon A, Vaughan ER, Cheetham JK, DeGryse R. Ocufen (flurbiprofen) in the treatment of ocular pain after radial keratotomy. CLAO J. 1994;20(2):131–138
  129. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308(5720):419–421
  130. Hankey GJ, Eikelboom JW. Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not?. Stroke. 2003;34(11):2736–2740
  131. Hanna C, Sharp JD. Ocular absorption of indomethacin by the rabbit. Arch Ophthalmol. 1972;88(2):196–198
  132. Hariprasad SM, Callanan D, Gainey S, et al. Cystoid and diabetic macular edema treated with nepafenac 0.1%. J Ocul Pharmacol Ther. 2007;23(6):585–590
  133. Hattori Y, Hashizume K, Nakajima K, et al. The effect of long-term treatment with sulindac on the progression of diabetic retinopathy. Curr Med Res Opin. 2007;23(8):1913–1917
  134. Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol. 1999;127(3):253–259
  135. Heier JS, Topping TM, Baumann W, et al. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology. 2000;107(11):2034–2038discussion 2039
  136. Hendricks RL, Barfknecht CF, Schoenwald RD, et al. The effect of flurbiprofen on herpes simplex virus type 1 stromal keratitis in mice. Invest Ophthalmol Vis Sci. 1990;31(8):1503–1
  137. Henrich WL. Nephrotoxicity of nonsteroidal anti-inflammatory agents. Am J Kidney Dis. 1983;2(4):478–484
  138. Herbort CP, Mermoud A, Schnyder C, Pittet N. Anti-inflammatory effect of diclofenac drops after argon laser trabeculoplasty. Arch Ophthalmol. 1993;111(4):481–483
  139. Hersh PS, Rice BA, Baer JC, et al. Topical nonsteroidal agents and corneal wound healing. Arch Ophthalmol. 1990;108(4):577–583
  140. Hirneiss C, Neubauer AS, Kampik A, Schonfeld CL. Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction: a prospective, randomized, double-masked study. Graefes Arch Clin Exp Ophthalmol. 2005;243(8):768–773
  141. Hoskins HD, Hetherington J, Minckler DS, et al. Complications of laser trabeculoplasty. Ophthalmology. 1983;90(7):796–799
  142. Hotchkiss ML, Robin AL, Pollack IP, Quigley HA. Nonsteroidal anti-inflammatory agents after argon laser trabeculoplasty. A trial with flurbiprofen and indomethacin. Ophthalmology. 1984;91(8):969–976
  143. Hu W, Criswell MH, Ottlecz A, et al. Oral administration of lumiracoxib reduces choroidal neovascular membrane development in the rat laser-trauma model. Retina. 2005;25(8):1054–1064
  144. Hurvitz LM, Spaeth GL, Zakhour I, et al. A comparison of the effect of flurbiprofen, dexamethasone, and placebo on cyclocryotherapy-induced inflammation. Ophthalmic Surg. 1984;15(5):394–399
  145. in t' Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345(21):1515–21
  146. Irvine SR. A newly defined vitreous syndrome following cataract surgery. Am J Ophthalmol. 1953;36(5):499–619
  147. Isawi H, Dhaliwal DK. Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use. J Cataract Refract Surg. 2007;33(9):1644–1646
  148. Ismail RA, Sallam A, Zambarakji HJ. Pseudophakic macular edema and oral acetazolamide: an optical coherence tomography measurable, dose-related response. Eur J Ophthalmol. 2008;18(6):1011–1013
  149. Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130(4):469–476
  150. Jackson WB. Differentiating conjunctivitis of diverse origins. Surv Ophthalmol. 1993;38(Suppl):91–104
  151. Jacobson DR, Dellaporta A. Natural history of cystoid macular edema after cataract extraction. Am J Ophthalmol. 1974;77(4):445–447
  152. Jampol LM. Pharmacologic therapy of aphakic and pseudophakic cystoid macular edema. 1985 update. Ophthalmology. 1985;92(6):807–810
  153. Jampol LM. Pharmacologic therapy of aphakic cystoid macular edema. A review. Ophthalmology. 1982;89(8):891–897
  154. Jaros PA, DeLuise VP. Pingueculae and pterygia. Surv Ophthalmol. 1988;33(1):41–49
  155. Johnson EI, Dunlop ME, Larkins RG. Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature. Curr Eye Res. 1999;18(2):79–82
  156. Johnson MW. Etiology and treatment of macular edema. Am J Ophthalmol. 2009;147(1):11–21e11
  157. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999;5(12):1418–1423
  158. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002;16(3):438–440
  159. Kahaly GJ, Roesler HP, Kutzner J, et al. Radiotherapy for thyroid-associated orbitopathy. Exp Clin Endocrinol Diabetes. 1999;107(Suppl 5):S201–S207
  160. Kaiser PK, Pineda R. A study of topical nonsteroidal anti-inflammatory drops and no pressure patching in the treatment of corneal abrasions. Corneal Abrasion Patching Study Group. Ophthalmology. 1997;104(8):1353–1359
  161. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation. 2003;27(5):281–291
  162. Karim MM, Hayashi Y, Inoue M, et al. COX-2 expression in retinoblastoma. Am J Ophthalmol. 2000;129(3):398–401
  163. Kawaguchi T, Kida T, Nemoto S, et al. Effect of bromfenac ophthalmic solution on ocular inflammation and corneal epithelial barrier function following cataract surgery. Folia Ophthalmol Jpn. 2003;54:276–279
  164. Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000;24(4):371–384
  165. Kent AR, Dubiner HB, Whitaker R, et al. The efficacy and safety of diclofenac 0.1% versus prednisolone acetate 1% following trabeculectomy with adjunctive mitomycin-C. Ophthalmic Surg Lasers. 1998;29(7):562–569
  166. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes. 2001;50(7):1636–1642
  167. Kern TS, Miller CM, Du Y, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes. 2007;56(2):373–379
  168. Khan HA, Amitava AK. Topical diclofenac versus dexamethasone after strabismus surgery: a double-blind randomized clinical trial of anti-inflammatory effect and ocular hypertensive response. Indian J Ophthalmol. 2007;55(4):271–275
  169. Khosravi E, Elena PP, Hariton C. Allergic conjunctivitis and uveitis models: reappraisal with some marketed drugs. Inflamm Res. 1995;44(1):47–54
  170. Kim A, Stark WJ. Are topical NSAIDs needed for routine cataract surgery?. Am J Ophthalmol. 2008;146(4):483–485
  171. Kim SJ, Adams NA, Toma HS, et al. Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. Retina. 2008;28(4):595–605
  172. Kim SJ, Belair ML, Bressler NM, et al. A method of reporting macular edema after cataract surgery using optical coherence tomography. Retina. 2008;28(6):870–876
  173. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology. 2007;114(5):881–889
  174. Kim SJ, Lo WR, Hubbard GB, et al. Topical ketorolac in vitreoretinal surgery: a prospective, randomized, placebo-controlled, double-masked trial. Arch Ophthalmol. 2008;126(9):1203–1208
  175. Kim SJ, Martin DF, Hubbard GB, et al. Incidence of postvitrectomy macular edema using optical coherence tomography. Ophthalmology. 2009;116(8):1531–1537
  176. Kitao N, Shimoji H, Fukuda M. Post-marketing surveillance of bromfenac (Bronuck) ophthalmic solution. Atarashii Ganka. 2005;22:1299–1308
  177. Klein BE, Klein R, Lee KE, Danforth LG. Drug use and five-year incidence of age-related cataracts: The Beaver Dam Eye Study. Ophthalmology. 2001;108(9):1670–1674
  178. Klein R, Klein BE, Jensen SC, et al. Medication use and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol. 2001;119(9):1354–1359
  179. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137(3):486–495
  180. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385–389
  181. Kothari HV, Lee WH, Ku EC. An alternate mechanism for regulation of leukotriene production in leukocytes: studies with an anti-inflammatory drug, sodium diclofenac. Biochim Biophys Acta. 1987;921(3):502–511
  182. Kraff MC, Martin RG, Neumann AC, Weinstein AJ. Efficacy of diclofenac sodium ophthalmic solution versus placebo in reducing inflammation following cataract extraction and posterior chamber lens implantation. J Cataract Refract Surg. 1994;20(2):138–144
  183. Kraff MC, Sanders DR, Jampol LM, et al. Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology. 1982;89(8):885–890
  184. Ku EC, Lee W, Kothari HV, Scholer DW. Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med. 1986;80(4B):18–23
  185. Kulshrestha MK, Rauz S, Goble RR, et al. The role of preoperative subconjunctival mydricaine and topical diclofenac sodium 0.1% in maintaining mydriasis during vitrectomy. Retina. 2000;20(1):46–51
  186. Kwok AK, Lam DS, Ng JS, et al. Ocular–hypertensive response to topical steroids in children. Ophthalmology. 1997;104(12):2112–2116
  187. Laibovitz RA, Koester J, Schaich L, Reaves TA. Safety and efficacy of diclofenac sodium 0.1% ophthalmic solution in acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther. 1995;11(3):361–368
  188. Lam S, Beck RW, Hall D, Creighton JB. Atonic pupil after cataract surgery. Ophthalmology. 1989;96(5):589–590
  189. Lane LS, Jansen PD, Lahav M, Rudy C. Circulating prostacyclin and thromboxane levels in patients with diabetic retinopathy. Ophthalmology. 1982;89(7):763–766
  190. Lane SS, Modi SS, Lehmann RP, Holland EJ. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg. 2007;33(1):53–58
  191. Laurell CG, Zetterstrom C. Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery. Br J Ophthalmol. 2002;86(12):1380–1384
  192. Leibowitz HM, Bartlett JD, Rich R, et al. Intraocular pressure–raising potential of 1.0% rimexolone in patients responding to corticosteroids. Arch Ophthalmol. 1996;114(8):933–937
  193. Leopold IH. Advances in ocular therapy: noncorticosteroid anti-inflammatory agents. Fifth annual Jules Stein Lecture. Am J Ophthalmol. 1974;78(5):759–773
  194. Lewis RA, Holgate ST, Roberts LJ, et al. Preferential generation of prostaglandin D2 by rat and human mast cells. Kroc Found Ser. 1981;14:239–254
  195. Lin JC, Rapuano CJ, Laibson PR, et al. Corneal melting associated with use of topical nonsteroidal anti-inflammatory drugs after ocular surgery. Arch Ophthalmol. 2000;118(8):1129–1132
  196. Ling TL, Combs DL. Ocular bioavailability and tissue distribution of [14C]ketorolac tromethamine in rabbits. J Pharm Sci. 1987;76(4):289–294
  197. Lobes LA, Grand MG. Incidence of cystoid macular edema following scleral buckling procedure. Arch Ophthalmol. 1980;98(7):1230–1232
  198. Lobo CL, Faria PM, Soares MA, et al. Macular alterations after small-incision cataract surgery. J Cataract Refract Surg. 2004;30(4):752–760
  199. Lyons CJ, Hakin KN, Watson PG. Topical flurbiprofen: an effective treatment for episcleritis?. Eye. 1990;4(Pt 3):521–525
  200. Mahoney J, Waterbury L. (±) 5 benzoyl-1,2-dihydro-3H pyrrolo [1,2a] pyrrole-1-carboxylic acid (RS-37619): a non-irritating ophthalmic anti-inflammatory agent. Invest Ophthalmol Vis Sci. 1983;24:151–159
  201. Maier TJ, Tausch L, Hoernig M, et al. Celecoxib inhibits 5-lipoxygenase. Biochem Pharmacol. 2008;76(7):862–872
  202. Malhotra M, Majumdar DK. Aqueous, oil, and ointment formulations of ketorolac: efficacy against prostaglandin E2-induced ocular inflammation and safety: a technical note. AAPS PharmSciTech. 2006;7(4):96
  203. Maloney SC, Fernandes BF, Castiglione E, et al. Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients. Retina. 2009;29(2):176–180
  204. Margalit E, Kugler LJ, Brumm MV, et al. The safety of intraocular ketorolac in rabbits. Invest Ophthalmol Vis Sci. 2006;47(5):2093–2099
  205. Marshall JC, Fernandes BF, Di Cesare S, et al. The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. Carcinogenesis. 2007;28(9):2053–2058
  206. Masuda K. Anti-inflammatory agents: Non-steroidal anti-inflammatory drugs, in Sears, ML (ed). Pharmacology of the Eye. Springer-Verlag, New York, 1984, pp.539–51
  207. McDonald HR, Verre WP, Aaberg TM. Surgical management of idiopathic epiretinal membranes. Ophthalmology. 1986;93(7):978–983
  208. McGeer EG, McGeer PL. Innate immunity in Alzheimers disease: a model for local inflammatory reactions. Mol Interv. 2001;1(1):22–29
  209. McGeer PL, Sibley J. Sparing of age-related macular degeneration in rheumatoid arthritis. Neurobiol Aging. 2005;26(8):1199–1203
  210. Mentes J, Erakgun T, Afrashi F, Kerci G. Incidence of cystoid macular edema after uncomplicated phacoemulsification. Ophthalmologica. 2003;217(6):408–412
  211. Meredith TA, Reeser FH, Topping TM, Aaberg TM. Cystoid macular edema after retinal detachment surgery. Ophthalmology. 1980;87(11):1090–1095
  212. Mermoud A, Pittet N, Herbort CP. Inflammation patterns after laser trabeculoplasty measured with the laser flare meter. Arch Ophthalmol. 1992;110(3):368–370
  213. Meyer E, Kraus E, Zonis S. Efficacy of antiprostaglandin therapy in vernal conjunctivitis. Br J Ophthalmol. 1987;71(7):497–499
  214. Miller D, Gruenberg P, Miller R, Bergamini MV. Topical flurbiprofen or prednisolone. Effect on corneal wound healing in rabbits. Arch Ophthalmol. 1981;99(4):681–682
  215. Mirshahi A, Djalilian A, Rafiee F, Namavari A. Topical administration of diclofenac (1%) in the prevention of miosis during vitrectomy. Retina. 2008;28(9):1215–1220
  216. Missotten L, Richard C, Trinquand C. Topical 0.1% indomethacin solution versus topical 0.1% dexamethasone solution in the prevention of inflammation after cataract surgery. The Study Group. Ophthalmologica. 2001;215(1):43–50
  217. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol. 2002;47(Suppl 1):S203–S218
  218. Miyake K, Masuda K, Shirato S, et al. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Jpn J Ophthalmol. 2000;44(1):58–67
  219. Miyake K, Sakamura S, Miura H. Long-term follow-up study on prevention of aphakic cystoid macular oedema by topical indomethacin. Br J Ophthalmol. 1980;64(5):324–328
  220. Miyake K. Indomethacin in the treatment of postoperative cystoid macular edema. Surv Ophthalmol. 1984;28(Suppl):554–568
  221. Miyake Y, Awaya S, Takahashi H, et al. Hyperbaric oxygen and acetazolamide improve visual acuity in patients with cystoid macular edema by different mechanisms. Arch Ophthalmol. 1993;111(12):1605–1606
  222. Miyake-Kashima M, Takano Y, Tanaka M, et al. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. Jpn J Ophthalmol. 2004;48(6):587–590
  223. Mombaerts I, Goldschmeding R, Schlingemann RO, Koornneef L. What is orbital pseudotumor?. Surv Ophthalmol. 1996;41(1):66–78
  224. Monnier Y, Zaric J, Ruegg C. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy. 2005;4(1):31–38
  225. Moreira H, McDonnell PJ, Fasano AP, et al. Treatment of experimental Pseudomonas keratitis with cyclo-oxygenase and lipoxygenase inhibitors. Ophthalmology. 1991;98(11):1693–1697
  226. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954–959
  227. Napoli SA, Helm C, Insler MS, et al. External ocular inflammatory effects of lipoxygenase enzyme products. Ann Ophthalmol. 1990;22(1):30–34
  228. Naveh N, Belkin M, Ben-Chaim O, et al. Prostanoids in the vitreous of diabetic and nondiabetic human eyes with retinal detachment. Ophthalmic Res. 1990;22(1):3–11
  229. Naveh-Floman N, Moisseiev J. Prostanoids and thromboxane A2 involvement in diabetic retinopathy. Metab Pediatr Syst Ophthalmol. 1982;6(3–4):321–325
  230. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol Suppl. 1997;49:6–8
  231. Nesburn AB. Immunological aspects of ocular herpes simplex disease, in Suran A, Gery I, Nussenblatt RB (eds). Immunology of the Eye: Workshop III. Washington, DC, Information Retrieval, 1979, p21–42
  232. Neufeld AH, Sears ML. Prostaglandin and eye. Prostaglandins. 1973;4(2):157–175
  233. Noble AG, Tripathi RC, Levine RA. Indomethacin for the treatment of idiopathic orbital myositis. Am J Ophthalmol. 1989;108(3):336–338
  234. Nozaki M, Raisler BJ, Sakurai E, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA. 2006;103(7):2328–2333
  235. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081–1091
  236. O'Brien TP, Li QJ, Sauerburger F, et al. The role of matrix metalloproteinases in ulcerative keratolysis associated with perioperative diclofenac use. Ophthalmology. 2001;108(4):656–659
  237. O'Brien WM. Pharmacology of nonsteroidal anti-inflammatory drugs. Practical review for clinicians. Am J Med. 1983;75(4B):32–39
  238. Ohara K, Okubo A, Miyamoto T, et al. Effect of bromfenac sodium on postoperative inflammation. Jpn J Cataract Refract Surg. 2004;18:168–173
  239. Ohara K, Okubo A, Miyamoto T, et al. Prevention of miosis during cataract surgery by topical bromfenac sodium. Jpn J Clin Ophthalmol. 2004;58(7):1325–1328
  240. Ohji M, Kinoshita S, Ohmi E, Kuwayama Y. Marked intraocular pressure response to instillation of corticosteroids in children. Am J Ophthalmol. 1991;112(4):450–454
  241. Okhravi N, Odufuwa B, McCluskey P, Lightman S. Scleritis Surv Ophthalmol. 2005;50(4):351–363
  242. Olson NY, Lindsley CB, Godfrey WA. Nonsteroidal anti-inflammatory drug therapy in chronic childhood iridocyclitis. Am J Dis Child. 1988;142(12):1289–1292
  243. Palmer RM, Stepney RJ, Higgs GA, Eakins KE. Chemokinetic activity of arachidonic and lipoxygenase products on leuocyctes of different species. Prostaglandins. 1980;20(2):411–418
  244. Papa V, Russo S, Russo P, et al. Topical naproxen sodium for inhibition of miosis during cataract surgery. Prospective, randomized clinical trials. Eye. 2002;16(3):292–296
  245. Patel M, Chan CC. Immunopathological aspects of age-related macular degeneration. Semin Immunopathol. 2008;30(2):97–110
  246. Peterson WL, Cryer B. COX-1-sparing NSAIDs—is the enthusiasm justified?. JAMA. 1999;282(20):1961–1963
  247. Pfister RR, Murphy GE. Corneal ulceration and perforation associated with Sjogrens syndrome. Arch Ophthalmol. 1980;98(1):89–94
  248. Powell ED, Field RA. Diabetic retinopathy and rheumatoid arthritis. Lancet. 1964;2(7349):17–18
  249. Price MO, Price FW. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr Med Res Opin. 2004;20(12):2015–2019
  250. Rabiah PK, Fiscella RG, Tessler HH. Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Invest Ophthalmol Vis Sci. 1996;37(4):613–618
  251. Radtke N, Meyers S, Kaufman HE. Sterile corneal ulcers after cataract surgery in keratoconjunctivitis sicca. Arch Ophthalmol. 1978;96(1):51–52
  252. Raizman M. Corticosteroid therapy of eye disease. Fifty years later. Arch Ophthalmol. 1996;114(8):1000–1001
  253. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets. 2004;4(1):29–42
  254. Rao NA, Patchett R, Fernandez MA, et al. Treatment of experimental granulomatous uveitis by lipoxygenase and cyclo-oxygenase inhibitors. Arch Ophthalmol. 1987;105(3):413–415
  255. Ray S, DAmico DJ. Pseudophakic cystoid macular edema. Semin Ophthalmol. 2002;17(3–4):167–180
  256. Reiss GR, Wilensky JT, Higginbotham EJ. Laser trabeculoplasty. Surv Ophthalmol. 1991;35(6):407–428
  257. Rho DS. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg. 2003;29(12):2378–2384
  258. Rho DS. Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. Cornea. 2006;25(10):1266–1267author reply 1267–8
  259. Riendeau D, Charleson S, Cromlish W, et al. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can J Physiol Pharmacol. 1997;75(9):1088–1095
  260. Roberts CW. Comparison of diclofenac sodium and flurbiprofen for inhibition of surgically induced miosis. J Cataract Refract Surg. 1996;22(Suppl 1):780–787
  261. Roberts CW, Brennan KM. A comparison of topical diclofenac with prednisolone for postcataract inflammation. Arch Ophthalmol. 1995;113(6):725–727
  262. Rooklin AR, Lampert SI, Jaeger EA, et al. Posterior subcapsular cataracts in steroid-requiring asthmatic children. J Allergy Clin Immunol. 1979;63(6):383–386
  263. Rosenbaum JT, Robertson JE. Recognition of posterior scleritis and its treatment with indomethacin. Retina. 1993;13(1):17–21
  264. Rossetti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. The results of a meta-analysis. Ophthalmology. 1998;105(3):397–405
  265. Sabates NR, Sabates FN, Sabates R, et al. Macular changes after retinal detachment surgery. Am J Ophthalmol. 1989;108(1):22–29
  266. Sainz de la Maza M, Foster CS, Jabbur NS. Scleritis associated with systemic vasculitic diseases. Ophthalmology. 1995;102(4):687–692
  267. Salz JJ, Reader AL, Schwartz LJ, Van Le K. Treatment of corneal abrasions with soft contact lenses and topical diclofenac. J Refract Corneal Surg. 1994;10(6):640–646
  268. Samiy N, Foster CS. The role of nonsteroidal antiinflammatory drugs in ocular inflammation. Int Ophthalmol Clin. 1996;36(1):195–206
  269. Samuelsson B, Borgeat P, Hammarstrom S, Murphy RC. Leukotrienes: a new group of biologically active compounds. Adv Prostaglandin Thromboxane Res. 1980;6:1–18
  270. Sanders DR, Goldstick B, Kraff C, et al. Aqueous penetration of oral and topical indomethacin in humans. Arch Ophthalmol. 1983;101(10):1614–1616
  271. Sanders DR, Kraff MC, Lieberman HL, et al. Breakdown and reestablishment of blood–aqueous barrier with implant surgery. Arch Ophthalmol. 1982;100(4):588–590
  272. Sandoval HP, De Castro LE, Vroman DT, Solomon KD. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation. J Ocul Pharmacol Ther. 2006;22(4):251–257
  273. Sawaoka H, Tsuji S, Tsujii M, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest. 1999;79(12):1469–1477
  274. Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica. 2003;217(2):89–98
  275. Schwartz B. Physiological effects of corticosteroids on the eye, in Schwartz B (ed). Corticosteroids and the Eye. Boston, Little, Brown & Co, 1980, p 753
  276. Seitz B, Sorken K, LaBree LD, et al. Corneal sensitivity and burning sensation. Comparing topical ketorolac and diclofenac. Arch Ophthalmol. 1996;114(8):921–924
  277. Sennlaub F, Valamanesh F, Vazquez-Tello A, et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation. 2003;108(2):198–204
  278. Sharma A, Gupta R, Ram J, Gupta A. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J Ophthalmol. 1997;45(3):177–180
  279. Shen WY, Constable IJ, Chelva E, Rakoczy PE. Inhibition of diclofenac formulated in hyaluronan on angiogenesis in vitro and its intraocular tolerance in the rabbit eye. Graefes Arch Clin Exp Ophthalmol. 2000;238(3):273–282
  280. Sher NA, Krueger RR, Teal P, et al. Role of topical corticosteroids and nonsteroidal antiinflammatory drugs in the etiology of stromal infiltrates after excimer photorefractive keratectomy. J Refract Corneal Surg. 1994;10(5):587–588
  281. Shimazaki J, Fujishima H, Yagi Y, Tsubota K. Effects of diclofenac eye drops on corneal epithelial structure and function after small–incision cataract surgery. Ophthalmology. 1996;103(1):50–57
  282. Shimazaki J, Saito H, Yang HY, et al. Persistent epithelial defect following penetrating keratoplasty: an adverse effect of diclofenac eyedrops. Cornea. 1995;14(6):623–627
  283. Shiuey Y, Ambati BK, Adamis AP. A randomized, double-masked trial of topical ketorolac versus artificial tears for treatment of viral conjunctivitis. Ophthalmology. 2000;107(8):1512–1517
  284. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247–1255
  285. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56(3):387–437
  286. Simon LS, Mills JA. Nonsteroidal antiinflammatory drugs (second of two parts). N Engl J Med. 1980;302(22):1237–1243
  287. Simone JN, Pendelton RA, Jenkins JE. Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. J Cataract Refract Surg. 1999;25(5):699–704
  288. Singal N, Hopkins J. Pseudophakic cystoid macular edema: ketorolac alone vs. ketorolac plus prednisolone. Can J Ophthalmol. 2004;39(3):245–250
  289. Sitenga GL, Ing EB, Van Dellen RG, et al. Asthma caused by topical application of ketorolac. Ophthalmology. 1996;103(6):890–892
  290. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol. 1997;39:1–20
  291. Smiddy WE, Glaser BM, Michels RG, Vitale S. Miosis during vitreoretinal surgery. Retina. 1990;10(1):42–46
  292. Snir M, Axer-Siegel R, Friling R, Weinberger D. Efficacy of diclofenac versus dexamethasone for treatment after strabismus surgery. Ophthalmology. 2000;107(10):1884–1888
  293. Solomon KD, Cheetham JK, DeGryse R, et al. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology. 2001;108(2):331–337
  294. Solomon KD, Donnenfeld ED, Raizman M, et al. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. J Cataract Refract Surg. 2004;30(8):1653–1660
  295. Solomon KD, Turkalj JW, Whiteside SB, et al. Topical 0.5% ketorolac vs 0.03% flurbiprofen for inhibition of miosis during cataract surgery. Arch Ophthalmol. 1997;115(9):1119–1122
  296. Solomon KD, Vroman DT, Barker D, Gehlken J. Comparison of ketorolac tromethamine 0.5% and rimexolone 1% to control inflammation after cataract extraction. Prospective randomized double-masked study. J Cataract Refract Surg. 2001;27(8):1232–1237
  297. Solomon LD. Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen-CME Study Group I. J Cataract Refract Surg. 1995;21(1):73–81
  298. Souza Filho JP, Martins MC, Correa ZM, et al. The expression of cyclooxygenase 2 in retinoblastoma: primary enucleated eyes and enucleation after conservative treatment. Am J Ophthalmol. 2006;142(4):625–631
  299. Spaeth GL, Rodrigues MM, Weinreb S. Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects. Trans Am Ophthalmol Soc. 1977;75:353–381
  300. Srinivasan R, Madhavaranga . Topical ketorolac tromethamine 0.5% versus diclofenac sodium 0.1% to inhibit miosis during cataract surgery. J Cataract Refract Surg. 2002;28(3):517–520
  301. Staudt S, Miller DW, Unnebrink K, Holz FG. [Incidence and extent of postoperative macular edema following vitreoretinal surgery with and without combined cataract operation]. Ophthalmologe. 2003;100(9):702–707
  302. Stevenson DD. Diagnosis, prevention, and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol. 1984;74:617–22
  303. Stewart RH, Grillone LR, Shiffman ML, et al. The systemic safety of bromfenac ophthalmic solution 0.09%. J Ocul Pharmacol Ther. 2007;23(6):601–612
  304. Stewart RH, Kimbrough RL. Intraocular pressure response to topically administered fluorometholone. Arch Ophthalmol. 1979;97(11):2139–2140
  305. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimers disease and duration of NSAID use. Neurology. 1997;48(3):626–632
  306. Stjernschantz J. Autacoids and neuropeptides. In:  Sears M editors. Pharmacology of the Eye. Berlin: Springer; 1984;p. 311–365
  307. Stjernschantz JW. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Invest Ophthalmol Vis Sci. 2001;42(6):1134–1145
  308. Strelow SA, Sherwood MB, Broncato LJ, et al. The effect of diclofenac sodium ophthalmic solution on intraocular pressure following cataract extraction. Ophthalmic Surg. 1992;23(3):170–175
  309. Szerenyi K, Sorken K, Garbus JJ, et al. Decrease in normal human corneal sensitivity with topical diclofenac sodium. Am J Ophthalmol. 1994;118(3):312–315
  310. Takahashi H, Yanagi Y, Tamaki Y, et al. COX-2–selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model. Biochem Biophys Res Commun. 2004;325(2):461–466
  311. Takahashi K, Saishin Y, Mori K, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003;44(1):409–415
  312. Takamatsu F, Shiroyama N, Saito Y, Ichikawa K. Efficacy and adverse effects of bromfenac ophthalmic solution following cataract surgery. Rinsho Ganka. 2003;57(7):1233–1237
  313. Tan DT, Chee SP, Lim L, Lim AS. Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology. 1999;106(2):223–231
  314. Tauber J, Raizman MB, Ostrov CS, et al. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther. 1998;14(2):137–145
  315. Thakkinstian A, Han P, McEvoy M, et al. Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet. 2006;15(18):2784–2790
  316. Thaller VT, Kulshrestha MK, Bell K. The effect of pre-operative topical flurbiprofen or diclofenac on pupil dilatation. Eye. 2000;14(Pt 4):642–645
  317. Thomas MC. Diuretics, ACE inhibitors and NSAIDs—the triple whammy. Med J Aust. 2000;172(4):184–185
  318. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94(4):252–266
  319. Thygeson P. Controversies in Ophthalmology. Philadelphia, WB Saunders, 1977, pp 450–469
  320. Tinkelman DG, Rupp G, Kaufman H, et al. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol. 1993;38(Suppl):133–140
  321. Toker MI, Erdem H, Erdogan H, et al. The effects of topical ketorolac and indomethacin on measles conjunctivitis: randomized controlled trial. Am J Ophthalmol. 2006;141(5):902–905
  322. Tranos PG, Wickremasinghe SS, Stangos NT, et al. Macular edema. Surv Ophthalmol. 2004;49(5):470–490
  323. Trattler W, McDonald M. Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation. Cornea. 2007;26(6):665–669
  324. Trinquand C, Richard C, Arnaud B. Three-arm, double-masked study of two ophthalmic formulations of 0.1% indomethacin and 0.1% diclofenac in controlling inflammation after cataract surgery. Invest Ophthalmol Vis Sci. 1996;37:S590
  325. Tuft SJ, Watson PG. Progression of scleral disease. Ophthalmology. 1991;98(4):467–471
  326. Uchio E, Itoh Y, Kadonosono K. Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis. Ophthalmologica. 2007;221(3):153–158
  327. Urban RC, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol. 1986;31(2):102–110
  328. Ursell PG, Spalton DJ, Whitcup SM, Nussenblatt RB. Cystoid macular edema after phacoemulsification: relationship to blood–aqueous barrier damage and visual acuity. J Cataract Refract Surg. 1999;25(11):1492–1497
  329. Vander JF, Greven CM, Maguire JI, et al. Flurbiprofen sodium to prevent intraoperative miosis during vitreoretinal surgery. Am J Ophthalmol. 1989;108(3):288–291
  330. Vlajkovic G, Sindjelic R, Stefanovic I. Ketorolac as a pre-emptive analgesic in retinal detachment surgery: a prospective, randomized clinical trial. Int J Clin Pharmacol Ther. 2007;45(5):259–263
  331. Waitzman MB, King CD. Prostaglandin influences on intraocular pressure and pupil size. Am J Physiol. 1967;212(2):329–334
  332. WalportComplement MJ. First of two parts. N Engl J Med. 2001;344(14):1058–1066
  333. WalportComplement MJ. Second of two parts. N Engl J Med. 2001;344(15):1140–1144
  334. Walters T, Raizman M, Ernest P, et al. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007;33(9):1539–1545
  335. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96(13):7563–7568
  336. Waterbury LD, Flach AJ. Efficacy of low concentrations of ketorolac tromethamine in animal models of ocular inflammation. J Ocul Pharmacol Ther. 2004;20(4):345–352
  337. Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006;22(6):1133–1140
  338. Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol. 1976;60(3):163–191
  339. Weinberger D, Ron Y, Lichter H, et al. Analgesic effect of topical sodium diclofenac 0.1% drops during retinal laser photocoagulation. Br J Ophthalmol. 2000;84(2):135–137
  340. Weinreb RN, Robin AL, Baerveldt G, et al. Flurbiprofen pretreatment in argon laser trabeculoplasty for primary open-angle glaucoma. Arch Ophthalmol. 1984;102(11):1629–1632
  341. Weisz JM, Bressler NM, Bressler SB, Schachat AP. Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. Ophthalmology. 1999;106(9):1656–1659
  342. Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des. 2004;10(27):3331–3348
  343. Williams CP, Browning AC, Sleep TJ, et al. A randomised, double-blind trial of topical ketorolac vs artificial tears for the treatment of episcleritis. Eye. 2005;19(7):739–742
  344. Wilson HL, Schwartz DM, Bhatt HR, et al. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol. 2004;137(4):615–624
  345. Wittpenn JR, Silverstein S, Heier J, et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs. steroid alone in low-risk cataract surgery patients. Am J Ophthalmol. 2008;146(4):554–560
  346. Wolf EJ, Kleiman LZ, Schrier A. Nepafenac-associated corneal melt. J Cataract Refract Surg. 2007;33(11):1974–1975
  347. Wood TS, Stewart RH, Bowman RW, et al. Suprofen treatment of contact lens-associated giant papillary conjunctivitis. Ophthalmology. 1988;95(6):822–826
  348. Wright M, Butt Z, McIlwaine G, Fleck B. Comparison of the efficacy of diclofenac and betamethasone following strabismus surgery. Br J Ophthalmol. 1997;81(4):299–301
  349. Yablonski ME, Burde RM, Kolker AE, Becker B. Cataracts induced by topical dexamethasone in diabetics. Arch Ophthalmol. 1978;96(3):474–476
  350. Yamada M, Kawai M, Kawai Y, Mashima Y. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr Eye Res. 1999;19(4):300–304
  351. Yannuzzi LA, Klein RM, Wallyn RH, et al. Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. Am J Ophthalmol. 1977;84(4):517–519
  352. Yannuzzi LA, Landau AN, Turtz AI. Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology. 1981;88(9):947–954
  353. Yannuzzi LA. A perspective on the treatment of aphakic cystoid macular edema. Surv Ophthalmol. 1984;28(Suppl):540–553
  354. Yasojima K, Schwab C, McGeer EG, McGeer PL. Up-regulated production and activation of the complement system in Alzheimers disease brain. Am J Pathol. 1999;154(3):927–936
  355. Yavas GF, Ozturk F, Kusbeci T. Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. J Cataract Refract Surg. 2007;33(5):804–807
  356. Yee RW. Analgesic efficacy and safety of nonpreserved ketorolac tromethamine ophthalmic solution following radial keratotomy. Ketorolac Radial Keratotomy Study Group. Am J Ophthalmol. 1998;125(4):472–480
  357. Young BJ, Cunningham WF, Akingbehin T. Double-masked controlled clinical trial of 5% tolmetin versus 0.5% prednisolone versus 0.9% saline in acute endogenous nongranulomatous anterior uveitis. Br J Ophthalmol. 1982;66(6):389–391
  358. Yuen SJ, Rubin PA. Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch Ophthalmol. 2003;121(4):491–499
  359. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol. 1984;102(4):551–553

 The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article. Supported in part by unrestrictive grants from Research to Prevent Blindness, Inc, New York, New York (Drs. Jampol and Flach) and That Man May See, San Francisco, California (Dr. Flach). The authors would like to acknowledge the contributions of Dr. Hassanain S. Toma who assisted in preparation of this manuscript.

PII: S0039-6257(09)00191-X

doi: 10.1016/j.survophthal.2009.07.005

Survey of Ophthalmology
Volume 55, Issue 2 , Pages 108-133 , March 2010

Article Tools

* Image Usage & Resolution